Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Bladder Carcinoma”

136 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 136 results

Testing effectiveness (Phase 2)Ended earlyNCT03719300
What this trial is testing

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Anchiano Therapeutics Israel Ltd. 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Early research (Phase 1)Looking for participantsNCT04485013
What this trial is testing

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Who this might be right for
Cancer
Tizona Therapeutics, Inc 240
Large-scale testing (Phase 3)Study completedNCT01316874
What this trial is testing

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Who this might be right for
Carcinoma in SituBladder Cancer
Endo Pharmaceuticals 90
Testing effectiveness (Phase 2)UnknownNCT02886897
What this trial is testing

Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaBladder Cancer+3 more
Sun Yat-sen University 50
Early research (Phase 1)Study completedNCT03884556
What this trial is testing

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Who this might be right for
Solid TumorLymphoma
Trishula Therapeutics, Inc. 56
Large-scale testing (Phase 3)Ended earlyNCT02982395
What this trial is testing

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Samyang Biopharmaceuticals Corporation 36
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Early research (Phase 1)Study completedNCT00004065
What this trial is testing

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Who this might be right for
Bladder CancerBreast CancerColorectal Cancer+9 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT03960060
What this trial is testing

CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Who this might be right for
Solid TumorSoft Tissue SarcomaGastric Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 9
Early research (Phase 1)Study completedNCT01391143
What this trial is testing

Safety Study of MGA271 in Refractory Cancer

Who this might be right for
Prostate CancerMelanomaRenal Cell Carcinoma+4 more
MacroGenics 179
Very early researchUnknownNCT05180851
What this trial is testing

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study

Who this might be right for
Head and Neck CancerMelanomaBreast Cancer+4 more
Shanghai Fengxian District Central Hospital 28
Testing effectiveness (Phase 2)Study completedNCT01031875
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03179943
What this trial is testing

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06972615
What this trial is testing

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Who this might be right for
Non Muscle Invasive Bladder Cancer
BLATAM 37
Not applicableStudy completedNCT03301493
What this trial is testing

Genomic Testing and Resulting Medical Decisions

Who this might be right for
Cancer of Unknown OriginCancer RefractoryCancer of Stomach+12 more
Arbeitsgemeinschaft medikamentoese Tumortherapie 1,500
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Study completedNCT02115542
What this trial is testing

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Who this might be right for
Cancer of the Bile Duct
H. Lee Moffitt Cancer Center and Research Institute 39
Early research (Phase 1)Study completedNCT00045006
What this trial is testing

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01638533
What this trial is testing

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Who this might be right for
GliomaHematopoietic and Lymphoid Cell NeoplasmLymphoma+47 more
National Cancer Institute (NCI) 37
Load More Results